Niessner, Martin

[["dc.bibliographiccitation.firstpage","292"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","VISZERALCHIRURGIE"],["dc.bibliographiccitation.lastpage","299"],["dc.bibliographiccitation.volume","42"],["dc.contributor.author","Lorf, Thomas"],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Liersch, Torsten"],["dc.contributor.author","Niessner, Martin"],["dc.contributor.author","Schuetze, Gunther"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Becker, H."],["dc.date.accessioned","2018-11-07T10:58:26Z"],["dc.date.available","2018-11-07T10:58:26Z"],["dc.date.issued","2007"],["dc.description.abstract","40 % of patients suffering from colorectal cancer will develop liver metastases during the course of their disease. Advances in both surgical technique and perioperative management lead to a decrease in postoperative morbidity and mortality. Against the background of an increasing understanding of tumor biology as well as excellent survival data following hepatic resection, the indication for liver resection has been extended in specialized surgical centers. Similarly the intention to treat changed from a standardized resection towards an individual and interdisciplinary therapy including preoperative chemotherapy, staged liver resection and resection of extrahepatic disease. The aim of this study is to investigate the current value of hepatic resection for colorectal liver metastases in the interdisciplinary oncological concept. It specially addresses these challenging situations where palliative chemotherapy seemed to be the only reasonable way of therapy in past."],["dc.identifier.doi","10.1055/s-2007-981332"],["dc.identifier.isi","000254585100003"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/50476"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.issn","1435-3067"],["dc.title","Surgical therapy for colorectal liver metastases: Prospects and limits"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","09"],["dc.bibliographiccitation.journal","Zeitschrift für Gastroenterologie"],["dc.bibliographiccitation.volume","46"],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Liersch, Torsten"],["dc.contributor.author","Niessner, Martin"],["dc.contributor.author","Becker, H"],["dc.contributor.author","Langer, C"],["dc.date.accessioned","2019-11-26T13:22:46Z"],["dc.date.available","2019-11-26T13:22:46Z"],["dc.date.issued","2008"],["dc.identifier.doi","10.1055/s-0028-1089657"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/62675"],["dc.language.iso","de"],["dc.relation.issn","0044-2771"],["dc.relation.issn","1439-7803"],["dc.title","Kolorektale Lebermetastasen: hat der Zeitpunkt des Auftretens eine Bedeutung für das onkologische Konzept und die Prognose?"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","638"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Cancer"],["dc.bibliographiccitation.lastpage","649"],["dc.bibliographiccitation.volume","123"],["dc.contributor.author","Sahlmann, Carsten-Oliver"],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Niessner, Martin"],["dc.contributor.author","Dyczkowski, Jerzy"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Braulke, Friederike"],["dc.contributor.author","Meller, Birgit"],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Meller, Johannes"],["dc.contributor.author","Goldenberg, David M."],["dc.contributor.author","Liersch, Torsten"],["dc.date.accessioned","2018-11-07T10:27:25Z"],["dc.date.available","2018-11-07T10:27:25Z"],["dc.date.issued","2017"],["dc.description.abstract","BACKGROUND: In previous work, a single administration of anticarcinoembryonic antigen (anti-CEA) I-131-labetuzumab radioimmunotherapy (RIT) after complete resection of colorectal liver metastases was well tolerated and significantly improved survival compared with controls. In the current phase 2 trial, the authors studied repeated RIT in the same setting, examining safety, feasibility, and efficacy. METHODS: Sixty-three patients (median age, 64.5 years) received RIT at 40 to 50 millicuries/m(2) per dose. Before the receipt of RIT, restaging was performed with computed tomography/magnetic resonance imaging and 18 F-fluorodeoxyglucose-positron emission to confirm that patients were \"truly adjuvant.\" Patients who had elevated serum CEA levels or radiographically inconclusive new lesions were classified as \"possibly nonadjuvant,\" but they also received RIT. Time to progression (TTP), overall survival (OS), and cause-specific survival (CSS) were calculated. The median follow-up was 54 months. RESULTS: After the first course of RIT, 14 of 63 patients experienced National Cancer Institute Common Toxicity Criteria grade 4 hematotoxicity; 19 patients did not receive the second course of RIT because of impaired performance status (N=5) or relapse (N=14). After the second course of RIT, 9 of 44 patients experienced National Cancer Institute Common Toxicity Criteria grade 4 hematotoxicity. Five patients developed myelodysplastic syndrome (MDS) from 22 to 55 months after their last RIT. The median TTP, OS, and CSS for all patients were 16, 55, and 60 months, respectively. The \"truly adjuvant\" patients (N=39) had an improved median TTP (not reached vs 6.1 months; hazard ratio, 0.12; P<.001), OS (75.6 vs 33.4 months; hazard ratio, 0.44; P=.014), and CSS (not reached vs 41.4 months; hazard ratio, 0.42; P=.014) compared with \" possibly nonadjuvant\" patients (N=24). CONCLUSIONS: Repeated RIT with I-131-labetuzumab is feasible but is associated with hematotoxicity. Survival is very encouraging, especially for \"truly adjuvant\" patients. However, the maximum safe dose of I-131-labetuzumab is a single administration of 50 millicuries/m(2). (C) 2016 American Cancer Society."],["dc.description.sponsorship","University Medical Center Goettingen"],["dc.identifier.doi","10.1002/cncr.30390"],["dc.identifier.isi","000396841300015"],["dc.identifier.pmid","27763687"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/43229"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.relation.issn","1097-0142"],["dc.relation.issn","0008-543X"],["dc.title","Repeated Adjuvant Anti-CEA Radioimmunotherapy After Resection of Colorectal Liver Metastases: Safety, Feasibility, and Long-Term Efficacy Results of a Prospective Phase 2 Study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","633"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Langenbeck s Archives of Surgery"],["dc.bibliographiccitation.lastpage","641"],["dc.bibliographiccitation.volume","395"],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Liersch, Torsten"],["dc.contributor.author","Niessner, Martin"],["dc.contributor.author","Meller, Johannes"],["dc.contributor.author","Lorf, Thomas"],["dc.contributor.author","Becker, Heinz"],["dc.contributor.author","Ghadimi, B. Michael"],["dc.date.accessioned","2018-11-07T08:40:58Z"],["dc.date.available","2018-11-07T08:40:58Z"],["dc.date.issued","2010"],["dc.description.abstract","We evaluated individualized multimodal oncological strategies in patients with bilobular colorectal liver metastases (biCRC-LM) as well as their effect on R0 resection rates, disease-free survival (DFS), and overall survival (OS). Between January 2001 and December 2008, 64 patients were assigned to straightforward or two-stage liver resection +/- preoperative 5-fluorouracil (5FU)-based chemotherapy (CTx). Postoperative strategy after R0-resection was either \"wait and see\" or \"adjuvant\" therapy (3 cycles of CTx or anti-carcinoembryonic antigen (CEA)-radioimmunotherapy with (131)I-labetuzumab in a dose of 40-50 mCi/m(2)). Forty-three initially unresectable patients received preoperative CTx for downsizing of their biCRC-LM. Straightforward or two-stage liver resection was intended in 40 and 24 patients, respectively. Histopathologically confirmed R0-liver resection could be achieved in 47 patients. Surgical morbidity and mortality rates were 33% and 1.5%, respectively. Postoperatively, 26 patients received anti-cancer therapy (5 x CTx, 21 x anti-CEA-radioimmunotherapy). After R0-liver resection, median OS was significantly better compared to R1/R2 resections followed by palliative 5FU-CTx (38 versus 19 months, p = 0.035). There was no significant difference in DFS (p = 0.650) and OS (p = 0.435) between straightforward and two-stage liver resection. Compared to \"wait and see\" strategy, the application of postoperative therapy in adjuvant intent was associated with a better OS (p = 0.048). Extensive liver resection within multimodal treatment concepts is justified in patients with biCRC-LM when complete resection of all metastases seems to be achievable."],["dc.identifier.doi","10.1007/s00423-010-0604-7"],["dc.identifier.isi","000280241200005"],["dc.identifier.pmid","20213463"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/4991"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/19362"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","1435-2443"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Multimodal treatment options for bilobar colorectal liver metastases"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Oncology Research and Treatment"],["dc.bibliographiccitation.volume","39"],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Sahlmann, Carsten-Oliver"],["dc.contributor.author","Niessner, Martin"],["dc.contributor.author","Dyczkowski, Jerzy"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Braulke, Friederike"],["dc.contributor.author","Meller, Birgit"],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Meller, J."],["dc.contributor.author","Goldenberg, David M."],["dc.contributor.author","Liersch, Torsten"],["dc.date.accessioned","2018-11-07T10:20:51Z"],["dc.date.available","2018-11-07T10:20:51Z"],["dc.date.issued","2016"],["dc.format.extent","13"],["dc.identifier.isi","000371353700041"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/41966"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Karger"],["dc.publisher.place","Basel"],["dc.relation.issn","2296-5262"],["dc.relation.issn","2296-5270"],["dc.title","Repeated anti-CEA radioimmunotherapy (RIT) with 131I-Labetuzumab after complete resection of colorectal liver metastases - safety, feasibility and long-term efficacy results of a prospective phase-II-study"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","08"],["dc.bibliographiccitation.journal","Zeitschrift für Gastroenterologie"],["dc.bibliographiccitation.volume","53"],["dc.contributor.author","Homayounfar, K"],["dc.contributor.author","Sahlmann, C"],["dc.contributor.author","Niessner, Martin"],["dc.contributor.author","Dyczkowski, J"],["dc.contributor.author","Conradi, L"],["dc.contributor.author","Braulke, F"],["dc.contributor.author","Beißbarth, T"],["dc.contributor.author","Meller, B"],["dc.contributor.author","Ghadimi, M"],["dc.contributor.author","Meller, J"],["dc.contributor.author","Goldenberg, D"],["dc.contributor.author","Liersch, T"],["dc.date.accessioned","2019-11-26T13:34:37Z"],["dc.date.available","2019-11-26T13:34:37Z"],["dc.date.issued","2015"],["dc.identifier.doi","10.1055/s-0035-1559215"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/62676"],["dc.language.iso","de"],["dc.relation.issn","0044-2771"],["dc.relation.issn","1439-7803"],["dc.title","Phase II Studie mit wiederholter anti-CEA-Radioimmuntherapie (RIT) mit 131I-Labetuzumab nach kompletter Resektion kolorektaler Lebermetastasen: Langzeitsicherheit und -überleben"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1359"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","International Journal of Colorectal Disease"],["dc.bibliographiccitation.lastpage","1367"],["dc.bibliographiccitation.volume","27"],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Bleckmann, Annalen"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Sprenger, T."],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Lorf, Thomas"],["dc.contributor.author","Niessner, Martin"],["dc.contributor.author","Sahlmann, Carsten-Oliver"],["dc.contributor.author","Meller, J."],["dc.contributor.author","Becker, H."],["dc.contributor.author","Liersch, Torsten"],["dc.contributor.author","Ghadimi, B. Michael"],["dc.date.accessioned","2018-11-07T09:05:22Z"],["dc.date.available","2018-11-07T09:05:22Z"],["dc.date.issued","2012"],["dc.description.abstract","Bilobar colorectal liver metastases (CRLM) are often considered incurable or associated with poor prognosis even after R0 resection. In this single-center study, we evaluate the impact of CRLM spreading on recurrence-free survival (RFS) and cancer-specific overall survival (CSS) after R0 resection of CRLM with respect to multimodal treatment strategies including perioperative chemotherapy and multistep resections. Between January 2001 and December 2010, R0 resection could be achieved in 70 patients with bilobar and 100 with unilobar CRLM. Extent of disease, perioperative chemotherapy, surgical procedures, adjuvant treatment, histopathological workup, RFS, and CSS were compared between both cohorts. Forty-six (66 %) patients with bilobar and 26 (26 %) patients with unilobar CRLM received preoperative chemotherapy (p < 0.001). For bilobar CRLM, more extended and multistep resection including portal vein occlusion were performed (29 % versus 3 %; p < 0.001). Morbidity (39 % versus 28 %, p = 0.183) and mortality (1 % versus 3 %, p = 0.644) rates were comparable in both patients' cohorts. Postoperative therapy was applied in adjuvant intent to 42 (60 %) versus 51 (51 %) patients (p = 0.275). The 5-year RFS and CSS rates were 24 % versus 31 % (p = 0.169) and 42 % versus 55 % (p = 0.131), respectively. To our single-center experience, there is no significant effect of CRLM spreading (bilobar versus unilobar) on RFS and CSS rates. Bilobar CRLM are more likely to require extended multimodal efforts to achieve R0 resection."],["dc.identifier.doi","10.1007/s00384-012-1455-1"],["dc.identifier.isi","000309171200014"],["dc.identifier.pmid","22430890"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/8804"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/25298"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.issn","0179-1958"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Bilobar spreading of colorectal liver metastases does not significantly affect survival after R0 resection in the era of interdisciplinary multimodal treatment"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1009"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","International Journal of Colorectal Disease"],["dc.bibliographiccitation.lastpage","1017"],["dc.bibliographiccitation.volume","28"],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Bleckmann, Annalen"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Sprenger, T."],["dc.contributor.author","Lorf, Thomas"],["dc.contributor.author","Niessner, Martin"],["dc.contributor.author","Sahlmann, Carsten-Oliver"],["dc.contributor.author","Meller, J."],["dc.contributor.author","Liersch, Torsten"],["dc.contributor.author","Ghadimi, B. Michael"],["dc.date.accessioned","2018-11-07T09:23:05Z"],["dc.date.available","2018-11-07T09:23:05Z"],["dc.date.issued","2013"],["dc.description.abstract","Surgery is the standard of care for resectable colorectal liver metastases (CRC-LM). Unfortunately, 60 % of patients develop secondary metastatic recurrence (SMR) after R0-resection of CRC-LM. We investigated the impact of surgical re-intervention and chemotherapy (Ctx) on survival in a consecutive series of patients with SMR. From 01/2001 to 11/2011, 104 out of 178 consecutive patients with R0-resection of CRC-LM developed SMR and were evaluated. The impact of surgical and Ctx re-interventions on recurrence free (RFS) and cancer-specific survival (CSS) was analyzed. Median follow-up was 28.0 (95 %CI: 19.4-37.4) months. SMR occurred in 81 patients at a single site (49x liver, 18x lung, 14x other) and in 23 patients at multiple sites. Forty-two patients were scheduled for primary surgery. Fifty-three patients were classified as non-resectable and treated with median 5.0 [IQR, 3.0-10.0] cycles of Ctx, combined with an EGFR/VEGF-antibody in 27 patients. Nine patients received best supportive care only. R0/R1 resection could be achieved in 35 patients primarily and even in 8 patients secondarily after Ctx. Surgical morbidity and mortality were 16 and 0 %, respectively. The 5-year RFS rates for patients with R0 versus R1-resection were 22 and 24 % (p = 0.948). The 5-year CSS rate for R0/R1-resected patients was 38 % versus 10 % for those patients treated by Ctx alone (p < 0.001). In SMR, surgical re-intervention is feasible and safe in a remarkable number of patients and offers significantly longer CSS compared to patients without resection."],["dc.identifier.doi","10.1007/s00384-013-1648-2"],["dc.identifier.isi","000321912200014"],["dc.identifier.pmid","23371333"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/10297"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/29498"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.issn","0179-1958"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Metastatic recurrence after complete resection of colorectal liver metastases: impact of surgery and chemotherapy on survival"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Cancer Biotherapy and Radiopharmaceuticals"],["dc.bibliographiccitation.volume","23"],["dc.contributor.author","Sahlmann, C-O"],["dc.contributor.author","Liersch, Thorsten"],["dc.contributor.author","Niessner, M."],["dc.contributor.author","Becker, H."],["dc.contributor.author","Goldenberg, David M."],["dc.contributor.author","Meller, J."],["dc.date.accessioned","2018-11-07T11:12:19Z"],["dc.date.available","2018-11-07T11:12:19Z"],["dc.date.issued","2008"],["dc.format.extent","524"],["dc.identifier.isi","000259167300046"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/53636"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Mary Ann Liebert Inc"],["dc.publisher.place","New rochelle"],["dc.relation.conference","12th Conference on Cancer Therapy with Antibodies and Immunoconjugates"],["dc.relation.eventlocation","Parsippany, NJ"],["dc.relation.issn","1084-9785"],["dc.title","Repeated versus single dose anti-CEA radioimmunotherapy (RIT) with iodine-131-labetuzumab after R0 resection for colorectal liver metastases (CRC-LM)"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","409"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","International Journal of Colorectal Disease"],["dc.bibliographiccitation.lastpage","418"],["dc.bibliographiccitation.volume","24"],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Liersch, Thorsten"],["dc.contributor.author","Schuetze, Gunther"],["dc.contributor.author","Niessner, M."],["dc.contributor.author","Goralczyk, Armin Dietmar"],["dc.contributor.author","Meller, J."],["dc.contributor.author","Langer, C."],["dc.contributor.author","Ghadimi, B. Michael"],["dc.contributor.author","Becker, H."],["dc.contributor.author","Lorf, Thomas"],["dc.date.accessioned","2018-11-07T08:31:09Z"],["dc.date.available","2018-11-07T08:31:09Z"],["dc.date.issued","2009"],["dc.description.abstract","Patients with bilobular colorectal liver metastases (CRLM) experience poor prognosis, especially when curative resection cannot be achieved. However, resectability in these patients is often limited by low future remnant liver volume (FRLV). The latter can be enhanced by a two-stage liver resection, using portal vein ligation to induce liver hypertrophy. The aim of this prospective pilot study was to evaluate safety, secondary resectability, and time to recurrence of two-stage hepatectomy with portal vein ligation (PVL) and complete surgical clearance of the FRLV in patients with bilobular CRLM. Out of 24 patients (63 +/- 8.26 years) with extended bilobular CRLM (metachronous n = 10, synchronous n = 14), 18 received preoperative 5-FU-based chemotherapy combined with oxaliplatin or irinotecan. Staging included thoracoabdominal computed tomography and (18)F-fluorodeoxyglucose-positron emission tomography scans. First-stage procedure consisted of PVL, resection of all CRLM in the FRLV, and radiofrequency ablation (RFA) of CRLM situated near the future resection plane. During first-stage procedure, 7x RFA, 4x non-anatomical resections, and 4x bisegmentectomies were performed additionally to PVL. FRLV/body-weight ratio increased from 0.4% to 0.6% within 55 days (median) after PVL. Second-stage hepatectomy was performed in 19 patients without tumor progression. R0 resection was possible in 14 patients. During a median follow-up of 17 months, intrahepatic recurrence occurred in two, and extrahepatic recurrence in nine out of 14 patients. Two-stage hepatectomy with PVL and complete surgical clearance of FRLV is safe even after intensified systemic chemotherapy resulting in a curative resection rate of 58.3% (73.7% of re-explored cases)."],["dc.description.sponsorship","German Research Society (DFG)"],["dc.identifier.doi","10.1007/s00384-008-0620-z"],["dc.identifier.isi","000263683500007"],["dc.identifier.pmid","19084973"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?goescholar/3515"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/17054"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0179-1958"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Two-stage hepatectomy (R0) with portal vein ligation-towards curing patients with extended bilobular colorectal liver metastases"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]